- Home
- AQST vs ABX Comparison
AQST vs ABX Comparison
Compare AQST & ABX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$2.95
Company Overview
Basic Information| Metric | AQST | ABX |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 707.6M | 774.2M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | AQST | ABX |
|---|---|---|
| Price | $2.95 | $7.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $8.83 | N/A |
| AVG Volume (30 Days) | ★ 6.4M | 475.4K |
| Earning Date | 03-04-2026 | 11-06-2019 |
| Dividend Yield | N/A | ★ 2.48% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.12 |
| Revenue | $43,397,000.00 | ★ $196,551,131.00 |
| Revenue This Year | N/A | $97.86 |
| Revenue Next Year | $43.02 | $18.09 |
| P/E Ratio | ★ N/A | $67.88 |
| Revenue Growth | N/A | ★ 91.93 |
| 52 Week Low | $2.12 | $4.60 |
| 52 Week High | $7.55 | $9.61 |
Technical Indicators
Market Signals| Indicator | AQST | ABX |
|---|---|---|
| Relative Strength Index (RSI) | 23.93 | 38.31 |
| Support Level | $3.17 | $7.73 |
| Resistance Level | $3.55 | $8.67 |
| Average True Range (ATR) | 0.25 | 0.38 |
| MACD | -0.03 | -0.10 |
| Stochastic Oscillator | 2.06 | 3.38 |
Price Performance
Historical Comparison AQST
ABX
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.